diagnost tool
price close busi januari
global leader diagnost breast
imag surgic product focu women
health also sell medic aesthet
breast health pick steam less
busi usual reiter hold rais pt
consist pre-announc deliv good inch
guid level think leav room addit upward revis year
bigger question us much investor need see compani
beat typic conserv outlook good portion call center around
gross margin base convers manag post call
maintain outlook modest improv gm acknowledg
think downsid low love breast health molecular diagnost
franchis look get comfort manag abil curb
recent gm declin coupl rel modest top line growth though
make stride top line reiter hold rais pt
rev rep match pre-announc beat our/street prior
adj ep beat our/street deliv beat vs
model breast diagnost off-set shortfal
cynosur gyn/surg adj om top
adj gm y/i miss due continu product
mix geograph shift lower ou manag expect slight growth gm
part aid growth higher margin molecular diagnost
breast health great breast health rev beat prior
driven growth us breast health fastest pace
year growth ou fxn help new acquisit focal therapeut
faxitron rev addit new launch smartcurv paddl breast
stabil system perform dimens place
geniu unit us convert instal base
ou molecular diagnost remain key driver total ou rev
rev grew y/i fxn diagnost revenu beat
driven strong y/i molecular dx growth
cyno rev y/i miss indic take coupl
year return cyno product appropri label vitalia back
market invest clinic trial vitalia mona lisa touch
said fda letter receiv froze doc commun clinician want see
data claim product yesterday allergan said system sale
declin due price dynam us expect msd growth
coolsculpt sale driven ou recoveri neg read-through
guidanc despit solid beat top line narrowli rais
revenue guid midpoint report
rep adj ep
lower share count guid
street out-quart adj ep vs our/street
rev vs our/street prior
deliv averag quarterli revenu beat last quarter
count thu think guid may conserv
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
growth segment make formal comment prepar
remark call regard segment growth outlook howev
convers manag compani indic track ahead
goal breast health molecular diagnost track goal
cynosur previous indic formal comment expect gener
low-to-mid singl digit revenu growth segment except
breast health segment target mid-single-digit growth like
breast health hit msd hsd growth cyno hit neg lsd growth
year though possibl may come neg view
hold unchang target price januari
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price januari
diagnost tool
hold unchang target price januari
diagnost tool
